Company intelligence / Profile preview

SHcell

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

SHcell is a South Korean biotechnology company specializing in the development of advanced cell therapies, including Natural Killer (NK) cell and Mesenchymal Stem Cell (MSC) treatments. The company focuses on leveraging its proprietary cell culture and activation technologies to address high-unmet-need areas such as oncology and degenerative diseases. Their lead programs include autologous NK cell therapies for solid tumors and MSC-based treatments for autoimmune conditions. SHcell aims to provide personalized regenerative medicine and immunotherapy solutions through its specialized R&D and manufacturing infrastructure.

Therapeutic areas: OncologyImmunologyRheumatology
Modalities: NK cell therapyStem cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on SHcell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHcell.

Explore the full profile